(redirected from Aromatase inhibitors)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to Aromatase inhibitors: tamoxifen
See: deterrent
References in periodicals archive ?
Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.
Successful detection of (anti-) androgenic and aromatase inhibitors in pre-spawning adult fathead minnows (Pimephales promelas) using easily measured endpoints of sexual development.
And the breast cancer returned more frequently with tamoxifen than with aromatase inhibitors.
It found that aromatase inhibitors saved more lives than tamoxifen.
SAN DIEGO -- The aromatase inhibitor letrozole didn't help boys with short stature grow taller, but it did boost their testosterone to concerning levels in a small study at Children's Hospital Los Angeles.
Thirty-two percent of them used adjuvant tamoxifen only, 29% used an aromatase inhibitor only, 20% switched from adjuvant tamoxifen to an AI, and the rest used neither endocrine therapy.
Bhatnagar AS, Brodie AMH, Long BJ, Evans DB, Miller WR (2001) Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors.
She also notes that the risk reduction seen was not as much as seen with fellow aromatase inhibitor exemestane (Aromasin) in a previous study.
Additionally, for women who have breast cancer and high cholesterol, taking statins may delay or prevent resistance to endocrine therapies such as tamoxifen or aromatase inhibitors.
Consequently, aromatase inhibitor (AI)-induced masculinization has been recognized as one of the most effective means for verifying the involvement of endogenous estrogen in ovarian differentiation and sex inversion of genotypic females.
But I never addressed the joint and muscle pain that often accompanies the use of aromatase inhibitors.
Method: In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and placebo (randomly assigned in a 2:1 ratio) in 724 patients with hormone-receptor-positive advanced breast cancer who had recurrence or progression while receiving previous therapy with a nonsteroidal aromatase inhibitor in the adjuvant setting or to treat advanced disease (or both).